journal article·2025-03-19

Engineered Drug-Amphiphile Conjugate Nanoparticles for Targeted Inhibition of AQP4-Mediated NLRP3 Inflammasome Signaling in Collagen-Induced Rheumatoid Arthritis

Ajay Kumar, Rahul, Kanika, Jattin Kumar, Anas Ahmad, Aneesh Ali, Bhuvnesh Kumar, Shubham Mahajan, Nemat Ali, Rehan Khan

ACS Applied Materials & Interfaces· Volume 17· Issue 11
Publisher page

Abstract

Aquaporins (AQPs) are transmembrane proteins that transport water, small solutes, and molecules across cell membranes. Studies have reported the role of AQPs in the activation, migration, and proliferation of immune cells, thus modulating the pathogenesis of autoimmune disease. In joints, the enhanced AQP4 expression exaggerates pathological changes like hydrarthrosis, acidosis, and hyperosmotic stress-inducing dysfunction of the articular chondrocytes, leading to articular cartilage destruction in collagen-induced arthritis (CIA). Acetazolamide (AZM), a sulfonamide carbonic anhydrase inhibitor of AQP4, reversibly decreases water permeability through AQP4 and is a potential molecule for targeting AQP4 in the CIA. However, its low solubility and low bioavailability limit its therapeutic effectiveness. Therefore, in this study, we have synthesized a polyphenol drug (gallic acid) (GA) and an amphiphile (glycerol monostearate) (GMS) conjugate to self-assemble into nanoparticles and encapsulated with AZM. Apart from AZM, GA is known for its antioxidant and anti-inflammatory properties. Therefore, intra-articular injection of AZM@GA-GMS NPs efficiently downregulates the expression of AQP4 and associated NLRP3 inflammasome activation. Moreover, the NPs are cytocompatible and showed enzyme-responsive drug release and thus offer a promising therapeutic strategy for RA by inhibiting AQP4-mediated inflammatory pathways. This opens up an avenue for treatment for RA.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Gout, Hyperuricemia, Uric Acid · Inflammasome and immune disorders · Pulmonary Hypertension Research and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Chemical Biology Unit, Institute of Nano Science and Technology, Knowledge City, Sector 81, Mohali (SAS Nagar), Punjab 140306, India

Julia McFarlane Diabetes Research Centre (JMDRC) and Department of Microbiology, Immunology and Infectious Diseases, Snyder Institute for Chronic Diseases, and Hotchkiss Brain Institute

Cumming School of Medicine, University of Calgary

Department of Pharmacology & Toxicology, College of Pharmacy

King Saud University

Funding

Indian Council of Medical Research · Science and Engineering Research Board · King Saud University

References (43)

Show source-provided references
1. 10.18053/jctres.02.201603.00510.18053/jctres.02.201603.005 ↗
2. 10.1186/s12950-017-0153-810.1186/s12950-017-0153-8 ↗
3. 10.3389/fphys.2018.0010110.3389/fphys.2018.00101 ↗
4. Cai L. · Ann. Clin. Lab. Sci. · 2017 · 47 · 563
5. 10.1016/j.autrev.2022.10313110.1016/j.autrev.2022.103131 ↗
6. 10.1016/j.jsb.2008.11.01010.1016/j.jsb.2008.11.010 ↗
7. 10.1016/j.biopha.2020.11098510.1016/j.biopha.2020.110985 ↗
8. 10.3389/fimmu.2020.58059310.3389/fimmu.2020.580593 ↗
9. 10.3390/nu1205147910.3390/nu12051479 ↗
10. 10.1021/acs.jafc.0c0080710.1021/acs.jafc.0c00807 ↗
11. 10.1021/acsbiomaterials.9b0042710.1021/acsbiomaterials.9b00427 ↗
12. 10.1038/s41467-018-03691-110.1038/s41467-018-03691-1 ↗
13. 10.1016/j.biomaterials.2024.12274710.1016/j.biomaterials.2024.122747 ↗
14. 10.1021/acsbiomaterials.3c0051410.1021/acsbiomaterials.3c00514 ↗
15. Recent Progress in Microenvironment-Responsive Nanodrug Delivery Systems for the Targeted Treatment of Rheumatoid Arthritis - Liu - 2024 - WIREs Nanomedicine and Nanobiotechnology - Wiley Online Library. https://wires.onlinelibrary.wiley.com/doi/epdf/10.1002/wnan.2008 (accessed Jan 26, 2025).
16. 10.1002/adhm.20240193610.1002/adhm.202401936 ↗
17. 10.1039/D0TB01559H10.1039/D0TB01559H ↗
18. 10.1186/1471-2474-15-9310.1186/1471-2474-15-93 ↗
19. 10.3389/fphar.2023.128545510.3389/fphar.2023.1285455 ↗
20. 10.4049/jimmunol.169.5.264310.4049/jimmunol.169.5.2643 ↗
21. 10.3109/14756366.2016.116162010.3109/14756366.2016.1161620 ↗
22. 10.3390/ijms2124973910.3390/ijms21249739 ↗
23. 10.1155/2020/383021210.1155/2020/3830212 ↗
24. Synovial fluid matrix metalloproteinase-3 levels are increased in inflammatory arthritides whether erosive or not | Rheumatology | Oxford Academic. https://academic.oup.com/rheumatology/article-abstract/39/12/1357/1784191?redirectedFrom=fulltext (accessed July 10, 2024).10.1093/rheumatology/39.12.1357 ↗
25. 10.1111/sji.1298210.1111/sji.12982 ↗
26. 10.1111/j.1479-8077.2007.00305.x10.1111/j.1479-8077.2007.00305.x ↗
27. 10.3389/fimmu.2020.59136510.3389/fimmu.2020.591365 ↗
28. 10.1038/s41584-020-0419-z10.1038/s41584-020-0419-z ↗
29. 10.1007/s40744-020-00219-210.1007/s40744-020-00219-2 ↗
30. 10.1155/2011/76562410.1155/2011/765624 ↗
31. 10.1016/j.cyto.2021.15574210.1016/j.cyto.2021.155742 ↗
32. 10.1039/D2BM01994A10.1039/D2BM01994A ↗
33. 10.1021/acs.nanolett.9b0049610.1021/acs.nanolett.9b00496 ↗
34. 10.3390/molecules2811441410.3390/molecules28114414 ↗
35. 10.1093/rheumatology/39.9.100410.1093/rheumatology/39.9.1004 ↗
36. 10.1038/srep1471310.1038/srep14713 ↗
37. 10.1016/j.jns.2024.12321510.1016/j.jns.2024.123215 ↗
38. 10.46497/ArchRheumatol.2022.868810.46497/ArchRheumatol.2022.8688 ↗
39. 10.1016/j.yjmcc.2023.05.00310.1016/j.yjmcc.2023.05.003 ↗
40. 10.1016/j.bbrc.2015.02.02910.1016/j.bbrc.2015.02.029 ↗
41. 10.1039/D3NR03857B10.1039/D3NR03857B ↗
42. 10.1038/s41419-019-1413-810.1038/s41419-019-1413-8 ↗
43. 10.4049/jimmunol.140232110.4049/jimmunol.1402321 ↗